Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795791 | 0.89 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795548 | 0.88 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795981 | 0.87 | MAPT (0.44) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795300 | 0.83 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795437 | 0.83 | LMNA (0.42) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL29984375 | 0.83 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795490 | 0.83 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795928 | 0.82 | L3MBTL1 (0.43) | MAPTALDH1A1SMN1; SMN2RAB9AHTT | |
| SCHEMBL18795190 | 0.81 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18795192 | 0.81 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MAPT 4627/4885ALDH1A1 4290/4885SMN1; SMN2 4573/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | MAPT 4627/4885ALDH1A1 4290/4885SMN1; SMN2 4573/4885 |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MAPT 4627/4885ALDH1A1 4290/4885SMN1; SMN2 4573/4885 |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MAPT 4627/4885ALDH1A1 4290/4885SMN1; SMN2 4573/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | MAPT 4627/4885ALDH1A1 4290/4885SMN1; SMN2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.